We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BRAV3:BMFBOVESPABrava Energia SA Analysis

Data as of 2026-05-18 - not real-time

R$19.17

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Brava Energia trades around R$19.17, well below its DCF-derived fair value of R$39.23, implying an upside of roughly 25% if the model holds. The stock’s trailing P/E of 39.1x is markedly higher than the energy industry average of 22x, yet the forward P/E collapses to 3.5x thanks to a sharp rise in projected EPS, signaling strong earnings acceleration. Revenue growth of 9% and a gross margin near 27% demonstrate solid top‑line performance, but the company’s debt‑to‑equity ratio exceeds 170% and ROE is only 2%, raising concerns about balance‑sheet resilience and capital efficiency.
Technically, the price sits above the 20‑day SMA (18.76) but below the 50‑day SMA (19.26), with a neutral trend and a modest bullish MACD histogram (+0.036) and RSI at 53, suggesting limited short‑term momentum. Volume is decreasing and 30‑day volatility is high at over 40%, while beta is near zero, indicating the stock moves largely independent of broader market swings. The recent announcement that Ecopetrol is acquiring an equity stake could provide a strategic partnership boost, adding a catalyst to the otherwise subdued price action.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price hovering near support at R$17.24
  • Bullish MACD histogram but decreasing volume
  • High short‑term volatility (~41%)

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF upside of ~25% and low forward P/E
  • Ecopetrol equity stake announcement as a catalyst
  • Strong earnings growth outlook (forward EPS) and low beta

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Elevated debt‑to‑equity ratio and modest ROE
  • Sustained dividend at 0.66% with zero payout ratio
  • Sector cyclicality and exposure to Brazilian regulatory environment

Key Metrics & Analysis

Financial Health

Revenue Growth9.10%
Profit Margin1.96%
P/E Ratio39.1
ROE2.06%
ROA3.32%
Debt/Equity173.81
P/B Ratio0.8
Op. Cash FlowR$4.9B
Free Cash FlowR$1.7B
Industry P/E22.0

Technical Analysis

TrendNeutral
RSI53.2
SupportR$17.24
ResistanceR$21.46
MA 20R$18.76
MA 50R$19.26
MA 200R$17.62
MACDBullish
VolumeDecreasing
Fear & Greed Index89.61

Valuation

Fair ValueR$39.24
Target PriceR$23.95
Upside/Downside24.96%
GradeUndervalued
TypeBlend
Dividend Yield0.66%

Risk Assessment

Beta0.10
Volatility41.34%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.